Literature DB >> 973966

Assessment of antipyrine kinetics by measurement in saliva.

H S Fraser, J C Mucklow, S Murray, D S Davies.   

Abstract

The half-life of antipyrine has been estimated from saliva samples in ten subjects by a gas chromatographic method. Half-life, apparent volume of distribution and total body clearance estimated from saliva and plasma concentrations of antipyrine are not significantly different. The concentration of antipyrine in saliva is independent of flow rate within the range expected in healthy subjects in response to mechanical and sapid stimuli. Antipyrine estimation in saliva could facilitate many areas of phaamacokinetic research limited by the difficulty of obtaining serial plasma samples.

Mesh:

Substances:

Year:  1976        PMID: 973966      PMCID: PMC1428876          DOI: 10.1111/j.1365-2125.1976.tb00610.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  The permeability of the human parotid gland to a series of sulfonamide compounds, para-aminohippurate and inulin.

Authors:  S A KILLMANN; J H THAYSEN
Journal:  Scand J Clin Lab Invest       Date:  1955       Impact factor: 1.713

2.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

3.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

4.  Circadian rhythms in the flow rate and proportional contribution of parotid to whole saliva volume in man.

Authors:  C Dawes; B Y Ong
Journal:  Arch Oral Biol       Date:  1973-09       Impact factor: 2.633

5.  Relationship between theophylline concentration in plasma and saliva of man.

Authors:  R Koysooko; E F Ellis; G Levy
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

6.  Interindividual differences in rates of drug oxidation in man.

Authors:  D S Davies; S S Thorgeirsson; A Breckenridge; M Orme
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

7.  Application of salivary salicylate data to biopharmaceutical studies of salicylates.

Authors:  G Graham; M Rowland
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

  7 in total
  31 in total

1.  Clinical application of antipyrine half life in saliva in a patient with osteomalacia.

Authors:  H S Fraser; D Thompson; C Khan
Journal:  Br Med J       Date:  1976-06-19

Review 2.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

4.  Time-dependent variability of chloroquine secretion into human saliva.

Authors:  C O Onyeji; F A Ogunbona
Journal:  Pharm World Sci       Date:  1996-12

5.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

6.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

7.  Interaction between vigabatrin and phenytoin.

Authors:  E M Rimmer; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Anticonvulsant therapy and cortisol elimination.

Authors:  P J Evans; R F Walker; J R Peters; J Dyas; D Riad-Fahmy; J P Thomas; E Rimmer; L Tsanaclis; M F Scanlon
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

9.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

10.  Reduction of circulating 25-hydroxyvitamin D by antipyrine.

Authors:  P F Wilmana; M J Brodie; J C Mucklow; H S Fraser; E L Toverud; D S Davies; C T Dollery; C J Hillyard; I Macintyre; B K Park
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.